PDF herunterladen
Thromb Haemost 1990; 64(03): 438-444
DOI: 10.1055/s-0038-1647333
Original Article
Schattauer GmbH Stuttgart

The Protective Effect of Heparin in a Dog Model of Rethrombosis Following Pharmacologic Thrombolysis

Sherry Voytik
*   The Hillenbrand Biomedical Engineering Center, Purdue University, W. Lafayette, IN, U.S.A.
,
Stephen F Badylak
*   The Hillenbrand Biomedical Engineering Center, Purdue University, W. Lafayette, IN, U.S.A.
,
Sandra Burke
#   The Dept. of Pharmacology (D-46R) and Pharmaceutical Products Division, Thrombolytic Venture (D-48R), Abbott Laboratories, Abbott Park, IL, U.S.A.
,
Richard E Klabunde
#   The Dept. of Pharmacology (D-46R) and Pharmaceutical Products Division, Thrombolytic Venture (D-48R), Abbott Laboratories, Abbott Park, IL, U.S.A.
,
Jack Henkin
#   The Dept. of Pharmacology (D-46R) and Pharmaceutical Products Division, Thrombolytic Venture (D-48R), Abbott Laboratories, Abbott Park, IL, U.S.A.
,
Abby Simmons
*   The Hillenbrand Biomedical Engineering Center, Purdue University, W. Lafayette, IN, U.S.A.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 15. März 1990

Accepted after revision 26. Juni 1990

Publikationsdatum:
04. September 2018 (online)

  als PDF herunterladen  Lizenzen und Reprints

Summary

Rethrombosis is an important clinical problem for patients who have benefitted from pharmacologic thrombolysis. The present study describes a dog model of arterial thrombosis, which includes endothelial denudation, intimal damage, and stenosis, and is suitable for studying the phenomena of both thrombolysis and subsequent rethrombosis. The model was used to determine the effect of tissue-type plasminogen activator (t-PA), high and low dose heparin, and saline upon the incidence of rethrombosis after t-PA-induced thrombolysis. Initial thrombolysis with reflow was achieved with 0.4 mg/kg t-PA, intravenous bolus injection, followed immediately by 0.4 mg/kg t-PA, 30 min infusion, in 40 of 42 dogs (95%) that had an occlusive, 125I-labelled thrombus created in a segment of femoral artery. The 40 dogs in which reperfusion was achieved were randomly sorted into 4 groups of 10 each which then received either saline, t-PA (0.4 mg kg−1 infused over 1 h), low dose heparin (500 U bolus injection then 250 U h−1 for 24 h), or high dose heparin (1,500 U bolus injection then 500 U h−1 for 24 h). Sixty percent (6/10) of the saline treated dogs showed occlusive rethrombosis at 24 h. The incidence of occlusive rethrombosis was 9/10 in the t-PA treated group (p = NS), 3/10 in the lowdose heparin treated group (p = NS), and 0/10 in the high dose heparin treated group (p <0.01). Two smaller groups consisting of 5 dogs each were treated with either saline or high dose heparinalone (no t-PA). None of the dogs in either group showed thrombolysis with reflow. All of the high dose heparin treated dogs and half of the low dose heparin treated dogs had prolonged values for the prothrombin time, activated partial thromboplastin time, and thrombintime through 24 h. All dogs treated with t-PA followed by additional t-PA had transient prolongations of the coagulation test values and also had a decrease in the plasma α2-antiplasmin concentration. These results suggest that heparin, when givenin high enough doses to cause risk of hemorrhage, provides protection against arterial rethrombosis following t-PA induced thrombolysis in a dog model of this clinically relevant problem.

 

  • References

  • 1 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, sobel BE, Leinbach Rc, Brinker JA, Ludbrook pA, yasuda I, Bulkley BH, Robison AK, Hutter AM, Bell wR, Spadaro JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized placebo-controlled trial. circulation 1984; 70: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 2 Gold HK, Leinbach Rc, palacios IF, yasuda T, Block pc, Buckley MJ, Akins CW, Daggett M, Austen WG. Coronary reocclusion after selective administration of streptokinase. Circulation 1983; 68: 150-154
    PubMedGoogle Scholar
  • 3 Gold HK, Leinbach RC, Garabedian HD, Yasuda I, Johns JA, Grossbard EB, Palacios I, Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347-352
    CrossrefPubMedGoogle Scholar
  • 4 Grines CL, Topol EJ, Bates ER, Juni JE, Walton Jr JA, O’Neill WW. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. Am Heart J 1988; 115: 1-7
    CrossrefPubMedGoogle Scholar
  • 5 Magnani B. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1989; 13: 194-196
    PubMedGoogle Scholar
  • 6 Mathey DG, Kuck K, Tilsner V, Krebber H, Bleifeld W. Nonsurgical coronary artery recanali zation in acute transmural myocardial infarction. Circulation 1981; 63: 489-497
    CrossrefPubMedGoogle Scholar
  • 7 Merz W, Dorf R, Rentrop P, Blanke H, Karsch KR, Mathey DG, Kremer R, Rutsch W, Schmutzler H. Evaluation of the effectiveness of intracoronary streptokinase infusion in acute myocardial infarction: postprocedure management and hospital course in 204 patients. Am Heart J 1981; 102: 1181-1187
    CrossrefPubMedGoogle Scholar
  • 8 The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986 314. 1465-1471
    PubMedGoogle Scholar
  • 9 Yasuda T, Gold HK, Fallon J, Leinbach RC, Collen D. Coronary reocclusion after recombinant human tissue-type plasminogen activator: studies with a residual stenosis model. Circulation 1984; 70: 11-259
    PubMedGoogle Scholar
  • 10 Johns JA, Gold HK. Management of coronary reocclusion following successful thrombolysis. In: Acute Coronary Intervention Topol EJ. ed Alan R Liss; New York: 1988: 95-10
  • 11 Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988; 318: 1512-1520 and 1585-95
    CrossrefPubMedGoogle Scholar
  • 12 Gash AK, Spann JE, Sherry S, Belber AD, Carabello BA, McDonough MT, Mann RH, McCann WD, Gault JH, Gentzler RD. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986; 57: 175-177
    CrossrefPubMedGoogle Scholar
  • 13 Brown BG, Gallery CA, Badger RS. et al Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation 1986; 73: 653-661
    CrossrefPubMedGoogle Scholar
  • 14 Harrison DG, Ferguson DW, Collins SM, Skorton DJ, Ericksen EE, Kioschos JM, Marcus ML, White CW. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesion. Circulation 1984; 69: 991-999
    CrossrefPubMedGoogle Scholar
  • 15 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987; 76: 142-154
    CrossrefPubMedGoogle Scholar
  • 16 Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natt p, Passamani ER, Williams DO, Zaret B. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissuetype plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987; 75: 817-829
    CrossrefPubMedGoogle Scholar
  • 17 Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in myocardial infarction (TIMI) Trial - Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11
    CrossrefPubMedGoogle Scholar
  • 18 Timmis GC, Mammen EF, Ramos RG, Gordon S, Gangadharan V, Hauser AM, Westveer DC, Stewart JR. Hemorrhage vs. rethrombosis after thrombolysis for acute myocardial infarction. Arch Intern Med 1986; 146: 667-672
    CrossrefPubMedGoogle Scholar
  • 19 Hirsh J. The use of anticoagulants in patients treated with streptokinase. In: New Concepts of Streptokinase Dosimetry Martin M, Schoop W, Hirsh J. eds Hans Huber, Bern, Stuttgart; Vienna: 1978: 135-40
  • 20 Schulmatr S, Locknef D, Grandqvist S, Bratt G, Paul C, Nyman D. A comparative randomized trial of low-dose versus high-dose streptokinase in deep vein thrombosis of the thigh. Thromb Haemostas 1984; 5l: 261-265
    PubMedGoogle Scholar
  • 21 Badylak SR, Poehlman ET, Williams C, Klabunde RE, Turek J, Schoenlein W. A simple canine model of arterial thrombosis with endothelial injury suitable for investigation of thrombolytic agents. J Pharmacol Methods 1988; 19: 293-304
    CrossrefPubMedGoogle Scholar
  • 22 Badylak SE, Voytik S, Klabunde RE, Henkin J, Leski M. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Thromb Res 1988; 52: 295-312
    CrossrefPubMedGoogle Scholar
  • 23 Kettner C, Shay E. D-Phe-Pro-ArgCH CL-A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
    CrossrefPubMedGoogle Scholar
  • 24 Mohler MA, Refino CJ, Chen SA, Chen AB. D-Phe-Pro-Argchloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-164
    PubMedGoogle Scholar
  • 25 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-225L. In: Progress in Chemical Fibrinolysis and Thrombolysis Vol.3 Davidson FJ, Samama MM, Desnoyers PC. eds Raven Press; New York: 1978: 315-322
  • 26 Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700-1707
    CrossrefPubMedGoogle Scholar
  • 27 Klabunde RE, Hemenway CC, Mohrman SJ, Henkin J, Badylak SE. Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogs. Thromb Res 1988; 50: 857-864
    CrossrefPubMedGoogle Scholar
  • 28 Guidelines for Blood-Material Interactions. Report of the National Heart, Lung, and Blood Institute Working Group. Revised 1985 203-240
    PubMedGoogle Scholar
  • 29 Topol EJ, Califf RM, George BS, Ereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581-588
    CrossrefPubMedGoogle Scholar
  • 30 Serruys PW, Wijns W, van den Brand M, Ribeiro Y, Fioretti P, Simoons MK, Kooijman CJ, Reiber JH C, Hugenholtz PG. Is transluminal coronary angioplasty mandatory after successful thrombolysis Quantitative coronary angiography study. Br Heart J 1983; 5A: 257-265
    PubMedGoogle Scholar
  • 31 Sutton JM, Thylor GJ, Mickell FL, Moses HW, Korsmeyer C, Dove JT, Batchelder JE, Wellons Jr HA, Schneider-J A. Thrombolytic therapy followed by early revascularization for Scute myocardial infarction. Am J Cardiol 1986; 57: 1227-1231
    CrossrefPubMedGoogle Scholar
  • 32 ISIS (International Studies of Infarct Survival) Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987 8. 634-642
    PubMedGoogle Scholar
  • 33 Elwood PC, Cochrane AL, Murr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R. A randomized controlled trial: acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. B M J 1974; 1: 436-440
    CrossrefPubMedGoogle Scholar
  • 34 Coronary Drug Project Research Group Aspirin in coronary heart disease. J Chronic Dis 1976 29. 625-642
    PubMedGoogle Scholar
  • 35 Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German Austrian Aspirin Tiial. A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980; 6: V63-Y72
    PubMedGoogle Scholar
  • 36 Klimt CR, Stamler J. Persantine-Aspirin Reinfarction Study Research Group: Second coronary prevention with persantine and aspirin. J Am Coll Cardiol 1985; 5: 505
    PubMedGoogle Scholar
  • 37 Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979; ii: 1313-1315
    PubMedGoogle Scholar